Literature DB >> 9788595

p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.

R Ravi1, B Mookerjee, Y van Hensbergen, G C Bedi, A Giordano, W S El-Deiry, E J Fuchs, A Bedi.   

Abstract

The p53 tumor suppressor gene plays an instrumental role in transcriptional regulation of target genes involved in cellular stress responses. p53-dependent transactivation and transrepression require its interaction with p300/CBP, a coactivator that also interacts with the RelA subunit of nuclear factor-kappaB. We find that p53 inhibits RelA-dependent transactivation without altering RelA expression or inducible kappaB-DNA binding. p53-mediated repression of RelA is relieved by p300 overexpression and the increased RelA activity conferred by p53-deficiency is counteracted by either transactivation domain-deficient p300 fragments that bind RelA or a transdominant mutant of IkappaB alpha. Our results suggest that p53 can regulate diverse kappaB-dependent cellular responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788595

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.

Authors:  Wei-Chien Huang; Tsai-Kai Ju; Mien-Chie Hung; Ching-Chow Chen
Journal:  Mol Cell       Date:  2007-04-13       Impact factor: 17.970

2.  MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

Review 3.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

4.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

5.  Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.

Authors:  C A Pise-Masison; R Mahieux; H Jiang; M Ashcroft; M Radonovich; J Duvall; C Guillerm; J N Brady
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

6.  Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus.

Authors:  Koichi Watashi; Makoto Hijikata; Ayako Tagawa; Takahiro Doi; Hiroyuki Marusawa; Kunitada Shimotohno
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

7.  The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response.

Authors:  M Leech; J R Xue; A Dacumos; P Hall; L Santos; Y Yang; M Li; A R Kitching; E F Morand
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

8.  High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failure.

Authors:  Mun-Kit Choy; Mehregan Movassagh; Lee Siggens; Ana Vujic; Martin Goddard; Ana Sánchez; Neil Perkins; Nichola Figg; Martin Bennett; Jason Carroll; Roger Foo
Journal:  Genome Med       Date:  2010-06-14       Impact factor: 11.117

9.  Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.

Authors:  Nadine Rohwer; Christof Dame; Anja Haugstetter; Bertram Wiedenmann; Katharina Detjen; Clemens A Schmitt; Thorsten Cramer
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

10.  Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.

Authors:  Michael R Garbati; Gökçen Alço; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2009-11-30       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.